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Background: Recently, we reported an association of a novel cancer testis (CT) antigen, sperm-associated antigen 9
(SPAG9) expression in breast cancer clinical samples, indicating its potential role in carcinogenesis. Around 15%
breast cancers are designated as triple-negative for which treatment modalities are limited. Therefore, in the
present study, we assessed the role of SPAG9 in triple-negative breast cancer cells.
Methods: SPAG9 mRNA and protein expression was investigated in various breast cancer cells of different hormone
receptor status and different subtypes by employing reverse transcriptase-polymerase chain reaction (RT-PCR), real time
PCR, Western blotting, indirect immunofluorescence (IIF) and fluorescence activated cell sorting (FACS). Employing
plasmid-based small interfering RNA (siRNA) approach, knockdown of SPAG9 was carried out in triple-negative breast
cancer cells, MDA-MB-231, to assess its role on various malignant properties in vitro and in vivo.
Results: SPAG9 mRNA and protein expression was detected in all breast cancer cells. Further, IIF results showed that
SPAG9 was predominantly localized in the cytoplasm of breast cancer cells. FACS analysis revealed distinct SPAG9
surface localization in breast cancer cells. Gene silencing of SPAG9 resulted in significant reduction in cellular proliferation,
colony forming ability, migration, invasion and cellular motility of MDA-MB-231 cells. Further, ablation of SPAG9
expression resulted in reduction in the tumor growth of human breast cancer xenograft in nude mice in vivo.
Conclusions: In summary, our data indicated that down regulation of SPAG9 reduces growth and invasive potential of
triple-negative breast cancer cells, suggesting that SPAG9 may be a potential target for therapeutic use.
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Breast cancer is the most common cause of cancer-related
deaths among women worldwide, with the highest mortal-
ity incidence in developing countries [1]. Breast cancer
is a complex disease which has different histotypes and
molecular subtypes based on molecular profiling with
different prognostic and therapeutic implications. Recent
studies have documented that breast cancer disease is a
resultant of accumulation of genomic [2] and epigenomic
[3] alterations resulting in reduced apoptosis, unchecked* Correspondence: anil@nii.res.in
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reproduction in any medium, provided the orproliferation, increased motility and invasion abilities and
metastasis in various other distant sites [4]. In this re-
gard, understanding the underlying mechanisms involved
in such process would eventually reveal the novel target
molecules involved in the disease progression and may
help in cancer treatment.
In clinical practice, breast cancer treatment modalities
are based on the specific proteins that are expressed in
cancerous tissue specimen. Majority of the breast cancer
patients express proteins such as estrogen receptor (ER)
and progesterone receptor (PR) for which targeted hor-
mone therapy is available with better clinical outcome
[5]. In addition, around 15-20% patients express human
epidermal growth factor receptor 2 (HER2) protein, for
which effective trastuzumab therapy is available with goodtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancers are designated as triple-negative and are character-
ized as ER negative (ER-), PR negative (PR-) and HER2
negative (HER2-) [7]. Triple-negative breast cancer patients
represent an important clinical challenge because these pa-
tients do not respond to endocrine therapy or any other
available targeted agents. Therefore, it is necessary to
investigate and characterize target molecules in triple-
negative breast cancers for better cancer management.
Earlier few studies have reported the expression of novel
proteins in triple-negative breast cancers; however none of
these proteins have been used in clinical setup [8]. There-
fore, it is important to characterize the novel targets to un-
ravel the biological pathways and modes of progression in
order to develop new candidate molecules and therapies.
In this regard, a unique class of tumor antigens designated
as cancer testis (CT) antigens has been reported to have
aberrant expression in various tumors, restricted expres-
sion in the testis and no or low expression in other somatic
tissues [9]. CT antigens have been proposed to play pivotal
role in various malignant properties of cancer cells [10].
Employing gene silencing approach, knockdown of CT an-
tigens could be specifically targeted and their involvement
in carcinogenesis could be investigated which may lead to
novel treatment modalities. Therefore, understanding the
involvement of CT antigen may be a good approach to
study the molecular mechanism involved in breast cancer.
Recently, we reported an association of sperm-associated
antigen 9 (SPAG9) expression, a new member of CT
antigen family, in various types of cancers [9]. Using
plasmid-based small interfering RNA (siRNA) approach
to knockdown SPAG9, we demonstrated significant re-
duction in cellular proliferation, colony forming ability,
cellular migration, invasion and wound healing capacity
in different types of cancers [11-13]. Interestingly, we also
demonstrated an association of SPAG9 immuno-reactivity
score (IRS) in early grades of breast cancer patients. In
addition, 88% breast cancer specimens showed SPAG9 ex-
pression independent of tumor stages and grades [14]. Col-
lectively, our data suggested that SPAG9 could be playing a
potential role in various malignant properties of breast
tumorigenesis.
In the present study, we investigated the SPAG9 ex-
pression in different breast cancer cell line models of dif-
ferent hormone receptor status and different subtypes.
Further, involvement of SPAG9 was investigated for vari-
ous malignant properties in triple-negative MDA-MB-231
cells, employing siRNA approach. Our data revealed that
SPAG9 mRNA and protein expression was detected in all
breast cancer cells. In addition, relative qPCR data demon-
strated 20 to 52 folds higher expression of SPAG9 mRNA
in MCF-7, MDA-MB-231, BT-474 and SK-BR-3 breast
cancer cells as compared to normal mammary epithelial
cells. SPAG9 was also shown to be anchored on the plasmamembrane of breast cancer cells. Employing gene silencing
approach, knockdown of SPAG9 gene revealed that SPAG9
plays an important role in cellular proliferation, colony
forming ability, migration and invasion. Furthermore,
in vivo breast xenograft studies in nude mice revealed that
SPAG9 siRNA plasmid injected mice showed significant
reduction in tumor growth. Collectively, our data has laid
foundation for SPAG9 to be used as a potential therapeutic
target for triple-negative breast cancer.
Material and method
Breast cancer cell lines
Four breast cancer cell lines of various subtypes, harboring
different hormone receptors, such as MCF-7 (luminal-A,
ER+ PR+ Her2-), BT-474 (luminal-B, ER+ PR+ Her2+),
SK-BR-3 (HER2 overexpressing, ER- PR- Her2+) and
MDA-MB-231 (highly metastatic basal, triple-negative ER-
PR- Her2-) were used in the study and were procured from
American Type Culture Collection (ATCC, Manassas, VA).
All the cells were cultured in recommended medium
under standard conditions. Human normal mammary
epithelial cells were purchased and maintained according
to manufacturer’s directions (Gibco, Life Technologies
Corporation, Carlbad, CA).
RNA isolation, reverse transcriptase-polymerase chain
reaction (RT-PCR) and real-time PCR
SPAG9mRNA was detected in normal mammary epithelial
cells and all breast cancer cells by extracting total RNA
using RNeasy Mini kit (Qiagen GmbH, Hilden, Germany)
and complementary DNA (cDNA) was synthesized using
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Carlsbad, CA) by following the manufacturer’s
protocol. RT-PCR was performed using cDNA template
and SPAG9 specific primers. Following SPAG9 primers
were designed from overlapping exons of SPAG9 in order
to avoid genomic DNA contamination during amplifica-
tion: SPAG9 Forward: 5′ GGGG GAATTCGATCAGGAA
CTTAAGGAACAGCAGAAGGAG 3′ SPAG9 Reverse: 5′
GGGG GGTACCCTGTTTCTCGTGCACCTGGCACACTT
GCAA 3′. RT-PCR was carried out by 30 amplification
cycles- 1 cycle of denaturation at 94°C for 2 min, 30 cycles:
denaturation at 94°C for 45 s; annealing at 50°C for 45 s;
extension at 72°C for 2 min; and a final elongation cycle
at 72°C for 7 min. Amplicon of samples were electro-
phoresed on 0.7% agarose gel and stained with ethidium
bromide and photographed under UV light in EC3 Im-
aging System (UVP, Upland, CA). Further, SPAG9 se-
quence was confirmed by cloning PCR product in TOPO
vector (Invitrogen, Carlsbad, CA). β-Actin mRNA expres-
sion was used as an internal control. SPAG9 mRNA ex-
pression was also checked in normal mammary epithelial
cells as a negative control. Real-time PCR was done using
10 ng of cDNA from normal mammary epithelial cells and
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Real time PCR master mix (Bio-Rad, CA, USA) on an
iCycler iQ multicolour real time PCR detection system
(Bio-Rad, CA, USA) according to manufacturer’s instruc-
tions. β-Actin was used as an internal control in all the
reactions. SPAG9 gene expression levels in each breast can-
cer cell line sample were subsequently normalized using
expression level of β-actin in the same mRNA sample as a
house keeping gene. All samples were measured in tripli-
cates. Primers were as follows:
SPAG9 Forward primer 5′- GAATTCGATCAGGAACT
TAAGGAACAGCAGAAGGAG-3′
SPAG9 Reverse primer 5′-GGTACCCTGTTTCTCGTG
CACCTGGCACACTTGCAA-3′
β-actin Forward primer 5′- ATCTGGCACCACACCT
TCTACAATGAGCTGCG-3′
β-actin Reverse primer 5′- CGTCATACTCCTGCTTG
CTGATCCACATCTGC-3′
Western blotting
Endogenous SPAG9 protein expression was validated in
all normal mammary epithelial cells and breast cancer
cells by Western blot analysis. Cell lysates were prepared
in lysis buffer [(1.5 mM Tris–HCl, pH 7.5, 150 mM NaCl,
0.5% sodium deoxycholate and 1% Nonidet P-40 (NP-40)
plus 1X Protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO)]. The protein concentration of the cell lysates
was determined by the bicinchoninic acid (BCA) method
as described in the manufacturer’s protocol (Thermo
Fisher Scientific Inc., Rockford, IL). Cell lysates (20 μg)
were denatured in laemmli loading buffer [10% glycerol,
5% 2-mercaptoethanol, 2% sodium dodecyl sulphate,
62.5 mM Tris (pH 6.8), 0.05% bromophenol blue] and were
resolved on 10% sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) gel. Further, protein was
electro-transferred to polyvinylidene difluoride (PVDF)
membrane in order to detect SPAG9 protein expression.
PVDF membranes were blocked with 5% non fat dry milk
and were incubated with anti-SPAG9 polyclonal antibody
(1:100 dilution) for 1h at RT. Subsequently, blots were incu-
bated with horseradish peroxidase (HRP)-conjugated goat
anti-rat IgG as a secondary antibody (Jackson Immuno-
Research Laboratories Inc., West Grove, PA) for 1h at RT.
The blots were developed with the immobilon western
chemiluminescent HRP substrate (Millipore Corporation,
Billerica, MA) according to the manufacturer’s protocol.
β-Actin was used as an intrinsic loading control for all
cell lysates analyzed.
Indirect immunofluorescence and fluorescence activated
cell sorting
Indirect immunofluorescence (IIF) assays and fluores-
cence activated cell sorting (FACS) analysis were carriedout to detect SPAG9 protein expression in breast cancer
cells as described earlier [13]. For IIF assays, briefly, cells
were fixed, permeabilized and were probed with anti-
SPAG9 antibody, followed by fluorescein isothiocyanate
(FITC)-conjugated goat anti-rat IgG as secondary anti-
body (Jackson ImmunoResearch Laboratories Inc., West
Grove, PA). Cell nucleus was stained with 4’ , 6-diamidino-
2-phenylindole [(DAPI) Sigma-Aldrich, St. Louis, MO].
Subsequently, images were captured using confocal
microscope [ZEISS LSM 510 Meta (Zeiss, Oberkochen,
Germany)]. For FACS analysis, cells were harvested and
analyzed for SPAG9 surface localization as described earl-
ier [13]. Fixed cells were probed with anti-SPAG9 poly-
clonal antibody followed by goat anti-rat IgG conjugated
with FITC as a secondary antibody. Cells stained with
secondary antibody only were used to account for the
background fluorescence. Data acquisition and analysis
was done using CellQuest v3.3 software.
Down regulation of SPAG9 using small interfering
RNA approach
In order to study the role of SPAG9 in various malignant
properties of breast cancer cells, transient transfection
was carried out in MDA-MB-231 cells using Lipofectamine
(Invitrogen, Carlsbad, CA) reagent, as described previously
[13]. Briefly, 6 μg of SPAG9 specific siRNA (SPAG9 siRNA)
and control siRNA (scrambled SPAG9) were used for
the in vitro experiments. Cells were harvested 48 h post-
transfection and cell lysate was prepared and analyzed by
Western blotting as explained above.
Cellular proliferation and colony formation assay
Cellular growth and colony forming ability were in-
vestigated in MDA-MB-231 cells post-transfection with
plasmid driven siRNA as described previously [13]. To
study the cellular proliferation, 2 × 104 MDA-MB-231
cells transfected with 6 μg of SPAG9 siRNA or control
siRNA were seeded in triplicates in 6-well plate. Cell num-
ber was counted with hemocytometer at three different
time points after seeding for 24 h, 48 h and 72 h. For col-
ony formation assay, a total of 400 to 1200 transfected cells
were seeded into 6-well plates. Ten days post-seeding, the
cells were fixed with 5% glutaraldehyde in Phosphate buff-
ered saline (PBS) and stained with 0.5% toluidine blue
(Sigma-Aldrich, St. Louis, MO). The colonies were manu-
ally counted after washing cells with PBS. Images of repre-
sentative fields were captured using Nikon Eclipse E 400
microscope (Nikon, Fukok, Japan). Each experiment was
repeated in triplicates.
Migration and invasion assays
To study the involvement of SPAG9 in various malignant
properties of breast cancer cells, cell migration and inva-
sion assays were performed using BD Biosciences Boyden
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described previously [13]. In migration assay, 2 × 105
transfected cells in 500 μl of serum free medium were
layered on the 8-μm pore inserts of the transwell
membrane in triplicate wells of 24-well plate. Foetal bovine
serum [(FBS) Biological Industries Israel Beit-Haemek
Ltd. Kibbutz Beit-Haemek, Israel] supplemented (750 μl)
medium was used as chemoattractant in the lower cham-
ber. Cells thus migrated to the lower chamber of the wells
were fixed with 5% glutaraldehyde in PBS, stained with
0.5% toluidine blue and were counted using bright field mi-
croscopy. For invasion assay, 8-μm pore inserts were
coated with 15 μg of Matrigel as a basement barrier
(Becton Dickinson Labware, Bedford, MA) and then
2 × 105 transfected cells were layered. Cells that invaded
through the artificial extracellular matrix and migrated to
the lower compartment of the Boyden chamber were fixed
and stained as explained above. Representative fields were
photographed under Nikon Eclipse E 400 microscope
(Nikon, Fukok, Japan). All the experiments were done in
triplicates.
Wound healing assay
Cellular motility was also studied by carrying out wound
healing assay as described previously [13]. Cells trans-
fected with 6 μg of SPAG9 siRNA or control siRNA
were seeded at a density of 1 × 106 on a 35-mm Petri
dish. After overnight incubation, on the confluent cell
monolayer, an artificial wound was carefully created
using 200-μl filtered tip. Subsequently, the petri dishes
were washed with serum free medium and cultured with
2% FBS medium and photomicrograph was taken imme-
diately at 0 h. Photomicrographs were also taken at 12 h,
24 h and 48 h under Nikon Eclipse E 400 microscope
(Nikon, Fukok, Japan). Within each assay the experi-
ments were performed in triplicates.
Breast cancer cells xenograft studies
To carry out in vivo studies, athymic nude mice (National
Institute of Immunology [NII], National Institutes of
Health, [S] nu/nu) were used in this study, after obtaining
approval from animal ethical committee of National
Institute of Immunology. Human tumor xenograft of
breast MDA-MB-231 cells was established by injecting
5 ×106 cells subcutaneously on the lower back, suspended
in Matrigel collagen basement membrane (BD Biosciences,
Bedford, MA). These nude mice were maintained at NII
animal facility in a pathogen-free atmosphere. After two
weeks, nude mice that had developed subcutaneous xeno-
graft tumors of around 50–100 mm3 were divided into two
treatment groups (8 mice in each group): SPAG9 siRNA
and control siRNA. Control siRNA or SPAG9 siRNA plas-
mids (50 μg) suspended in 200 μl of PBS were injected
intra-tumorally followed by a booster injection of 25 μgplasmid injected twice weekly for 7 weeks. Tumor growth
was measured regularly twice a week. Tumor volume (V)
was calculated by measuring tumor dimensions using
digital calipers as described earlier [12]. At the end of the
experiment, tumors were excised, fixed, embedded in par-
affin and sectioned for histological examination of SPAG9
and PCNA expression.
Immunohistochemical analysis
Immunohistochemical analysis was performed on 4-μm-
thick sections of tumor tissue excised from control
siRNA and SPAG9 siRNA mice using polyclonal anti-
SPAG9 antibody and mouse anti-PCNA antibody as
described earlier [11,12]. Briefly, sections were depara-
ffinized, rehydrated, washed with PBS (pH7.2) and were in-
cubated in methanolic H2O2 (45:5) for 45 minutes to block
and remove all traces of endogenous peroxidase. Subse-
quently, tissue sections were blocked with 5% normal goat
serum for 1 hour at RT and probed with polyclonal anti-
SPAG9 antibody for overnight at 4°C. After three washes
with PBS, sections were incubated with Horse reddish per-
oxidase–conjugated goat anti-rat IgG (Jackson Immuno-
Research Laboratories, West Grove, PA) as a secondary
antibody. After incubation sections were subjected to three
washings with PBS and the color was developed using 3,
3′-Diaminobenzidine (Sigma- Aldrich, St. Louis, MO)
as a substrate. Serial sections of same tissue specimens
were also processed for immunohistochemical staining for
PCNA using the same protocol. Slides were counterstained
with hematoxylin solution, mounted and observed under a
Nikon Eclipse E 400 microscope (Nikon, Fukuoka, Japan).
Six random fields of each tissue section were examined by
counting >500 cells under ×400 magnification.
Statistical analysis
The statistical significance of the results of in vitro and
in vivo data was determined by the Student’s t test using
the SPSS version 20.0 statistical software package (SPSS
Inc., Chicago, IL). A P-value of less than 0.05 was con-
sidered statistically significant. All experimental data are
presented as mean ± standard error.
Results
SPAG9 mRNA expression in breast cancer cell lines
RT-PCR analysis revealed that SPAG9 mRNA was found
in all breast cancer cell line models used in the present
study [MCF-7 (ER+/PR+/Her2- luminal-A subtype), SK-
BR-3 (ER-/PR-/Her2+ ERBB2 associated subtype), BT-
474 (ER+/PR+/Her2+ triple-positive luminal-B subtype)
and MDA-MB-231 (ER-/PR-/Her2- triple-negative basal
subtype)] as shown in Figure 1a. Human testis cDNA
was used as positive control which also revealed same
size PCR amplicon. Moreover, no expression of SPAG9
transcript was detected in normal mammary epithelial cells
Figure 1 SPAG9 expression in breast cancer cells. (a) RT-PCR analysis showed SPAG9 mRNA expression in testis and no expression in normal
mammary epithelial cells (NMEC). SPAG9 mRNA expression was observed in MCF-7, MDA-MB-231, BT-474 and SK-BR-3 cells. β-Actin gene
expression was used as an internal control. (b) Relative expression of SPAG9 mRNA in MCF7, MDA-MB-231, BT-474 and SK-BR-3 breast cancer cells
relative to NMEC. (c) Validation of SPAG9 protein expression in NMEC and breast cancer cells by Western blot analysis. SPAG9 reactive band was
detected in MCF-7, MDA-MB-231, BT-474 and SK-BR-3 cell lysates. However, no reactivity against SPAG9 was detected in NMEC. Lower panel
depicts the β-actin protein reactivity as an internal loading control in all breast cancer cells. (d) SPAG9 protein expression in breast cancer cells by
IIF assay. IIF assay revealed distinct cytoplasmic SPAG9 localization in fixed and permeabilized cells probed with anti-SPAG9 antibody in MCF-7,
MDA-MB-231, BT-474 and SK-BR-3 cells. Nuclei of the cells were stained blue with DAPI. All images were captured using confocal microscope
(Original magnification, ×630; objective, 63×). (e) SPAG9 surface localization in breast cancer cells. FACS analysis distinctly showed SPAG9 surface
localization in MCF-7, MDA-MB-231, BT-474 and SK-BR-3 cells probed with anti-SPAG9 antibody as depicted in histogram plot showing
displacement of fluorescence intensity on X axis (M1) as compared to fluorescence intensity of cells stained with secondary antibody only (M2).
Representative plots showed high percentages of distinct population of MCF-7 (94.79%), MDA-MB-231 (96.11%), BT-474 (97.39%) and SK-BR-3
(95.21%) cells showing SPAG9 surface localization as compared to cells stained with secondary antibody only.
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in cancerous cells. Further, PCR amplicon was subcloned
in TOPO vector and sequenced. Nucleotide sequencing
confirmed the SPAG9 mRNA sequence in all breast cancercells. Thus, our RT-PCR results indicated that SPAG9 gene
is expressed in all breast cancer cells independent of their
hormone receptor status or subtypes. We further assessed
SPAG9 mRNA expression in normal mammary epithelial
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cancer cell lines by quantitative real-time PCR. All breast
cancer cell lines evaluated displayed higher levels of SPAG9
expression, compared to control normal mammary cells
(Figure 1b). SPAG9 expression was around 20 fold higher
in MCF7, MDA-MB-231 and BT-474. However, 52 fold
higher SPAG9 expression was observed in SK-BR-3 as
compared to normal mammary cells.
SPAG9 protein expression in breast cancer cell lines
To validate the SPAG9 gene expression, endogenous
SPAG9 protein expression was further investigated by
Western blot analysis which revealed an immunoreactive
band in all the four breast cancer cells as shown in
Figure 1c. β-Actin reactive band revealed equal loading
of the lysate protein prepared from all breast cancer
cells. Subsequently, SPAG9 protein expression was in-
vestigated by IIF in fixed and permeabilized MCF-7,Figure 2 Gene silencing of SPAG9 using plasmid-mediated siRNA app
(scrambled SPAG9) were used to transfect MDA-MB-231 breast cancer cells
with control siRNA. However, cells transfected with SPAG9 siRNA revealed a
(b) Knockdown of SPAG9 inhibits cellular growth of breast cancer cells. Histo
transfected with SPAG9 siRNA as compared to cells transfected with control
performed in triplicates. (c) SPAG9 knockdown reduces colony forming abilit
siRNA showed significantly reduced (P < 0.001) colony forming ability in 400
control siRNA. (d) A representative photomicrograph of colony forming abil
MDA-MB-213 cancer cells. Columns indicate mean (n = 3); bars, standard err
siRNA. These results are representative of three independent experiments pMDA-MB-231, BT- 474 and SK-BR-3 cells (Figure 1d),
which revealed SPAG9 protein expression predominantly
in cytoplasm. Further, surface localization of SPAG9 pro-
tein was detected in all four breast cancer cells as dem-
onstrated by FACS analysis (Figure 1e). FACS analysis
clearly showed the displacement of fluorescence intensity
on the X-axis in breast cancer cells probed with anti-
SPAG9 polyclonal antibody indicating SPAG9 surface
localization in MCF-7, MDA-MB-231, BT-474 and SK-
BR-3 cells (Figure 1e). FACS analysis also demonstrated
high percentage of SPAG9 expressing cells showing
SPAG9 surface localization in MCF-7 (94.79%), MDA-
MB-231 (96.11%), BT-474 (97.39%) and SK-BR-3 (95.21%)
cells. As expected, no or very low shift in fluorescence
intensity was observed in cells probed with only sec-
ondary antibody. Collectively, IIF and FACS data sug-
gested that SPAG9 may be a potential target for cancer
immunotherapeutics.roach. SPAG9 specific siRNA (SPAG9 siRNA) and control siRNA
(a) No reduction in SPAG9 protein was observed in cells transfected
blation of SPAG9 protein. β-Actin protein was used as a loading control.
gram plot clearly shows significant growth reduction (P < 0.01) in cells
siRNA. Results are representative of three independent experiments
y of breast cancer cells. MDA-MB-231 cells transfected with SPAG9
–1200 cells in each histogram as compared to cells transfected with
ity treated with control siRNA or SPAG9 siRNA in 400, 800 and 1200
or. *; p < 0.01, **; p < 0.001 statistically significant compared with control
erformed in triplicates.
Sinha et al. Journal of Experimental & Clinical Cancer Research 2013, 32:69 Page 7 of 11
http://www.jeccr.com/content/32/1/69Gene silencing of SPAG9 inhibits cellular proliferation
and colony forming ability of MDA-MB-231 cells
Small interfering RNA mediated gene silencing approach
was used to selectively knockdown SPAG9 to study its
role in cellular proliferation and colony forming ability.
Highly aggressive triple-negative basal subtype MDA-
MB-231 cells were used for in vitro gene silencing studies.
SPAG9 siRNA construct transfected in MDA-MB-231 cells
revealed ablation of SPAG9 protein as compared to control
siRNA transfected cells as detected in Western blot ana-
lysis (Figure 2a). However, residual SPAG9 protein expres-
sion was also detected in SPAG9 siRNA transfected cells.
Subsequently, MDA-MB-231 cells transfected with SPAG9
siRNA revealed significant reduction in cellular growth
(P < 0.01) as compared to control siRNA transfected cells.
Cell growth was reduced by 32% post 72 h of treatment
(Figure 2b). Interestingly, colony forming ability was also
significantly reduced by (P < 0.001) for various cell num-
bers seeded for MDA-MB-231 cells (59%-78% for 400–
1200 cells) transfected with SPAG9 siRNA but not in
cells transfected with control siRNA (Figure 2c; 2d).
These results indicated that siRNA based knockdown













Figure 3 SPAG9 gene silencing significantly inhibited migration and inva
showed reduced number of migrated cells transfected with SPAG9 siRNA as co
reduction (P< 0.005) in the number of migrated cells transfected with SPAG9 s
on three experimental triplicates. (b) Knockdown of SPAG9 gene significantly re
photomicrograph showed SPAG9 siRNA transfected cells exhibit reduced invas
control siRNA transfected cells. (c) A histogram shows significant reduction (
MDA-MB-231 cells as compared to control siRNA transfected cells. Columns in
significant compared with control siRNA. These results are representative of thgrowth and colony forming ability of triple-negative MDA-
MB-231 cells.
Knockdown of SPAG9 inhibits migration and invasion
abilities of MDA-MB-231 cells
SPAG9 association with migratory and invasive abilities of
MDA-MB-231 cells was further investigated. Our results
showed a significant inhibition of 52.5% in migrating abil-
ity of MDA-MB-231 cells transfected with SPAG9 siRNA
(P < 0.005) as compared to control siRNA as depicted in
histogram (Figure 3a; 3c). Invasive ability of MDA-MB-231
cells was investigated using a reconstituted basement
membrane barrier (Matrigel). Our results revealed a signifi-
cant reduction of invasive ability (62.5%; P < 0.005) with
SPAG9 siRNA as compared to control siRNA distinctly
shown in histogram (Figure 3b; 3c). Our gene silencing
studies collectively suggests that SPAG9 may be involved
in migration and invasion of MDA-MB-231 cells.
Gene silencing of SPAG9 significantly reduces
cellular motility
The important feature of metastasis process is the spread









































sion ability of MDA-MB-231 cells. (a) Representative photomicrograph
mpared to control siRNA transfected cells. A histogram shows significant
iRNA as compared to control siRNA transfected cells. Observations based
duced invasion of MDA-MB-231 cells through the Matrigel. Representative
ion abilities through Matrigel-coated Transwell filters as compared to
P < 0.005) in the number of invaded cells in SPAG9 siRNA transfected
dicate mean (n = 3); bars, standard error. *; P < 0.005 statistically
ree independent experiments performed in triplicates.
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SPAG9 in cellular motility, an in vitro wound healing assay
was carried out. The motility of MDA-MB-231 cells was
found to be significantly retarded when transfected with
SPAG9 siRNA as compared to cells transfected with
control siRNA. Our results revealed a closure of wound
within 12h in control siRNA transfected cells, while
MDA-MB-231 cells transfected with SPAG9 siRNA failed
to close the wound scratch even after 48 h (Figure 4). This
data clearly indicated that SPAG9 is involved in cellular
motility and early spread of breast cancer cells, suggesting
that SPAG9 may be involved in migration and inva-
sion of MDA-MB-231 cells.
SPAG9 depletion reduced tumor growth in vivo
Our in vitro data indicated that ablation of SPAG9 expres-
sion by SPAG9 siRNA significantly reduced colony forma-
tion which led us to investigate its effect on human breast
xenograft tumor growth in nude mice in vivo. To deter-
mine the effect of SPAG9 siRNA or control siRNA onFigure 4 Down regulation of SPAG9 causes reduction in wound healin
with SPAG9 siRNA showed significantly reduced cellular motility even after
revealed closing of wound within 12 h. Results are from three independenttumor growth, mice were treated with control siRNA or
SPAG9 siRNA and were observed for 42 days. A represen-
tative photograph shows reduced tumor growth in SPAG9
siRNA treated group compared with control siRNA treated
group (Figure 5a). The tumor volume of mice injected with
SPAG9 siRNA showed a significant reduction in tumor
growth as compared to mice administered with control
siRNA (Figure 5b; P < 0.001). Furthermore, in order to in-
vestigate whether the reduction of tumor growth is a result
of ablation of SPAG9 expression, the xenograft tumors
were excised and processed for immunohistochemical
staining for SPAG9 protein expression. As depicted in
Figure 5c, the SPAG9 protein was ablated in SPAG9 siRNA
treated mice compared with mice treated with control
siRNA. Furthermore to investigate whether SPAG9 siRNA
treated animals which showed reduced tumor growth was
associated with reduced cellular proliferation, serial tumor
sections were probed for PCNA expression. Our data re-
vealed that there was significant reduction of PCNA ex-
pression (72%; P < 0.0001) in tumors treated with SPAG9g capacity of MDA-MB-231 cells. MDA-MB-231 cells transfected
48 h. In contrast, MDA-MB-231 cells transfected with control siRNA
experiments.
Figure 5 Effect of down regulation of SPAG9 expression in breast cancer xenograft model. (a) A representative photomicrograph showing
nude mice with tumor (arrows) treated with control siRNA or SPAG9 siRNA plasmid. (b) a graph representing tumor volume calculated on the
indicated days revealed significant reduction in the tumor growth in mice treated with SPAG9 siRNA plasmid compared with control siRNA
(n = 8; *, P < 0.0001). (c) Immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) and SPAG9 protein in control siRNA and SPAG9
siRNA treated tumors. Left panel- hematoxylin and eosin staining showing the histological cytostructure of the tumor of the control siRNA and
SPAG9 siRNA treated mice. Middle panel- shows the reduced SPAG9 expression probed with anti SPAG9 antibody in SPAG9 siRNA treated mice
tumors compared with control siRNA treated mice. Right panel- similarly shows the reduced PCNA expression in the SPAG9 siRNA treated mice
compared with control siRNA treated mice. (d) The histograph representing the number of SPAG9 expressing cells and PCNA expressing cells.
The histograph distinctly revealed the significantly reduced number of SPAG9 and PCNA expressing cells in SPAG9 siRNA compared with control
siRNA treated mice. Columns indicate mean; bars, standard error. * P < 0.0001, statistical significant. Original magnification, × 400; objective × 40.
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Figure 5c and histograms (Figure 5d). These results suggest
that SPAG9 may be a molecular target for novel cancer
treatment modalities.
Discussion
Breast cancer remains the major cause of death in
women worldwide. Recent reports indicate that majority
of cancer related deaths occur in economically weak and
developing countries, such as India [1]. The existing
treatment modalities for breast cancer patients are basedon expression of ER, PR and HER2 molecules. However, a
major challenge remains with the breast cancer patients
with triple-negative tumors for which there are no or lim-
ited therapy available and have poor prognosis [15]. There-
fore, in this regard we investigated the involvement of
a well characterized CT antigen, SPAG9 in breast cancer
using various breast cancer cell line models. Gene silencing
approach was employed to study the association of SPAG9
with early spread and metastasis in highly aggressive triple-
negative MDA-MB-231 breast cancer cells which may lead
to new therapeutic strategies.
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be associated with different stages and grades of various
tumors [9]. In addition, SPAG9 was also shown to be as-
sociated with cellular proliferation, migration and inva-
sion in squamous cell carcinoma-derived cervical cancer
(SiHa) [12], renal cell carcinoma (Caki-1) [11] and colon
cancer (COLO 205 and HCT 116) [13] cell line models,
respectively. Recently, we also demonstrated an associ-
ation of SPAG9 with early spread of breast carcinogen-
esis [14]. Collectively, our data indicates that SPAG9
may be a potential key molecule contributing towards
the early spread and metastasis. In this context, we in-
vestigated SPAG9 expression in breast cancer cells of
different histological subtypes, harboring different hor-
mone receptor.
So far very few studies have proposed an associ-
ation of CT antigens with cellular growth, migration
and invasion abilities in various breast cancer cell lines.
Earlier, X antigen family, member 1 (XAGE-1) was shown
to be expressed only in ER-negative breast cancer cell
lines (MDA-MB-231, SK-BR-3, and MDA-MB-468 cells),
and no expression in ER-positive breast cancer cell lines
(ZR-75-1, MCF-7, and BT-474 cells) [16] suggesting that
XAGE-1 transcription may be functional through estrogen
receptor pathway. Yet another well studied CT antigens,
melanoma antigen family A (MAGEA) and New York
oesophageal squamous cell carcinoma 1 (NY-ESO-1) were
reported to have expression in ER- negative breast cancer
cells [BT20 cells [17]. In contrast, it is important to men-
tion that in our study, SPAG9 expression was detected in
all breast cancer cells, independent of their hormone re-
ceptor status or HER2 expression pattern. Our RT-
PCR results confirmed SPAG9 mRNA expression in all
breast cancer cells which was further validated for protein
expression by Western blotting and IIF. We did not find
any discrepancy between SPAG9 mRNA and protein ex-
pression in all breast cancer cells. Further, our FACS data
revealed that SPAG9 protein was also localized on the
plasma membrane of MCF-7, MDA-MB-231, BT-474 and
SK-BR-3 breast cancer cells, indicating its putative use in
development of immunotherapeutic target for breast can-
cer treatment.
Metastasis is a complex process involving multiple steps
including epithelial mesenchymal transition (EMT) and
mesenchymal epithelial transition (MET) resulting in mi-
gration, invasion, colony forming abilities and subsequently
tumor growth at distant sites [18]. In this context, it is
important to investigate gene and gene products in-
volved in early spread, tumor progression and metastasis.
Plasmid-based siRNA approach was used to selectively
knockdown the expression of SPAG9 in MDA-MB-231
cells. Gene silencing approach has been employed in few
studies to investigate the biological role of CT antigens in
tumorigenesis and their effects on tumor progression. Ina recent study, knockdown of MAGE-D4B in triple-
negative breast cancer cell line model Hs578T demon-
strated a significant reduction in colony forming and
invasive abilities [19]. Further, employing gene silen-
cing approach, the role of well characterized CT antigens,
MAGE-C1 and MAGE-A3 were shown to promote
cellular growth and colony forming ability in myeloma
cells (Molp-8 and KMS-12-BM cells) [20]. Knockdown
of synovial sarcoma X (SSX) in melanoma cells (DFW)
also showed reduction in cell migration [21]. Similarly,
significant reduction in cellular motility by wound healing
assay was demonstrated by knockdown of sperm-associated
antigen 1 (SPAG1) suggesting a strong association of
SPAG1 with migration abilities in pancreatic cancer cells,
Panc1 [22]. It is important to mention that none of the
earlier studies demonstrated the effect of knockdown of
CT antigen on all of the key features of metastasis except
a recent study [23] suggesting the role of Melanoma
antigen gene-A3 (MAGE-A3) gene in invasion and angio-
genesis. Similarly, our study also revealed the involvement
of SPAG9 in cellular proliferation and migration suggesting
its potential role in early spread. Interestingly our study
showed that SPAG9 is involved in invasive potential of
MDA-MB-231 cells and down regulation of SPAG9 signifi-
cantly reduced the cellular growth, colony forming ability,
migratory and invasive ability and wound healing capacity
in these cells. Furthermore, knockdown of SPAG9 expres-
sion in vivo in nude mice also showed reduction in tumor
growth indicating its important role in breast cancer.
In conclusion, to the best of our knowledge, this is the
first report where we have put forth an evidence of poten-
tial role of SPAG9 in cellular growth, migration, invasion
and colony forming ability in highly aggressive triple-
negative MDA-MB-231 breast cancer cells. Furthermore
we also demonstrated that SPAG9 expression was higher
in all breast cancer cell compared to normal mammary epi-
thelial cells. In addition, in vivo xenograft studies further
strengthen the role of SPAG9 in breast cancer. Our study
provides an association between SPAG9 expression and its
potential role in breast cancer, and thus lays a foundation
for developing a promising therapeutic target for triple-
negative breast cancer.
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